Evidence map›Paper›PMID 38890242›Full record

SynthesisHigh blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension2024

Efficacy and Safety of Radiofrequency-Based Renal Denervation on Resistant Hypertensive Patients: A Systematic Review and Meta-analysis.

Luis Eduardo Rodrigues Sobreira, Fernando Baia Bezerra, Vitor Kendi Tsuchiya Sano, Artur de Oliveira Macena Lôbo, Jorge Henrique Cavalcanti Orestes Cardoso, Francinny Alves Kelly, Francisco Cezar Aquino de Moraes, Fernanda Marciano Consolim-Colombo

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Renal Denervation as a Novel Therapeutic Approach for Resistant Hypertension: Mechanisms, Efficacy and Future Directions.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Luis Eduardo Rodrigues SobreiraFederal University of Para, Altamira, 68371-040, Brazil. luis.med.sobreira@gmail.com.ORCID http://orcid.org/0009-0003-3006-5489
Fernando Baia BezerraAnhembi Morumbi University, Sao Jose dos Campos, 12230-002, Brazil.ORCID http://orcid.org/0009-0007-2587-4176
Vitor Kendi Tsuchiya SanoFederal University of Acre, Rio Branco, 69920-900, Brazil.ORCID http://orcid.org/0000-0001-8317-1857
Artur de Oliveira Macena LôboFederal University of Pernambuco, Recife, 50670-901, Brazil.ORCID http://orcid.org/0009-0003-0637-0387
Jorge Henrique Cavalcanti Orestes CardosoUniversity of Pernambuco, Recife, Pernambuco, 50100-130, Brazil.ORCID http://orcid.org/0000-0003-0316-8047
Francinny Alves KellyDante Pazzanese Cardiology Institute, Sao Paulo, 04012-909, Brazil.ORCID http://orcid.org/0000-0003-0706-6929
Francisco Cezar Aquino de MoraesFederal University of Para, Belem, 66075-110, Brazil.ORCID http://orcid.org/0000-0003-0623-8135
Fernanda Marciano Consolim-ColomboHeart Institute, Sao Paulo, 05403-900, Brazil.ORCID http://orcid.org/0000-0003-3220-019X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNew therapies for resistant hypertension (RH), including renal denervation (RDN), have been studied.

aimAccess the safety and effectiveness of radiofrequency-based RDN vs pharmacological treatment for RH.

methodsA thorough literature search was conducted across PubMed, EMBASE, and the Cochrane databases, focusing on studies that compared the effects of radiofrequency-based RDN versus pharmacological treatment for RH. Treatment effects for binary and continuous endpoints were pooled and used, respectively, odds-ratio (OR) and mean differences (MD) with 95% confidence intervals (CI) to analyze continuous outcomes.

resultsIn the 10 included studies, involving 1.182 patients, 682 received radiofrequency-based RDN. The follow-up period ranged from 6 to 84 months. Analysis revealed that the RDN group had a significant reduction in office systolic blood pressure (BP) (MD - 9.5 mmHg; 95% CI - 16.81 to - 2.29; P = 0.01), office diastolic BP (MD - 5.1 mmHg; 95% CI - 8.42 to - 2.80; P < 0.001), 24 h systolic BP (MD - 4.8 mmHg; 95% CI - 7.26 to - 2.42; P < 0.001). For 24 h diastolic BP RDN did not have a significant reduction (MD - 2.3 mmHg; 95% CI - 4.19 to - 0.52; P = 0.012). The heterogeneity between the studies was high, visible in the funnel and Baujat plots. The OR was non-significant for non-serious adverse events, but also clinically significant for hypertensive crises and strokes for the RDN group.

conclusionsWhile the pharmacological regimen of 3 or more anti-hypertensive, including a diuretic, still be the first-line option for RH treatment, our results support that radiofrequency-based RDN is superior in reducing global BP and is safe.

Indexed as

Catheter AblationDrug ResistanceHypertensionKidneySympathectomyAdultAgedAntihypertensive AgentsBlood PressureFemaleHumansMaleMiddle AgedRenal ArteryRisk FactorsTime FactorsAntihypertensive AgentsMeta-analysisRadiofrequency-based renal denervationRandomized controlled trialResistant hypertensionSystematic review

Identifiers

PMID38890242

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.